Clinical evidence, rooted in real-world impact

127 patients in RPM group • 65 in control group (OPTIMA).

Reduction of the total number of calls in RPM group (mean diff = -1.25 • p < 0.001), and specifically the number of call for visit preparation (mean diff = -2.7 • p < 0.001).

Increase number of calls for inter-cycles toxicities (mean diff = +1.48 • p < 0.001) → Optimized patient management.

The average number of calls per patient over 4 months of follow-up decreased from 5.6 to 1.9 with Cureety (p < 0.0001).

The average duration of calls per patient over 4 months decreased from 28.3 to 12.1 minutes (p = 0.0018).

The average duration of stay for hospitalized patients decreased from 39.3 to 15.3 days (p = 0.02).

Sensitivity of 78.3% to flag patient in need of medical attention (orange or red).

Specificity of 94.4% to not flag patient in need of medical attention (green or yellow).

Clinically relevant to complement standard of care.

In total, on the 697 remote monitoring classifications.

Sensitivity of 80.9% and Specificity of 94.9%.

High performance of the classification algorithm for radiotherapy patients.

Wide range of patient profiles in terms of age, gender, cancer types and treatments.

Adopted by all types of HCPs and care centers, private and public, large and small.

More than 80% of patients satisfies or very satisfied.

Distribution of clinical classifications varies according to the treatment type, in line with the expected relative toxicity of treatment types.

Strong growth in usage since 2019, accelerating with reimbursement start.

Good representativity of cancer types and treatment types.

Adoption at scale in a large Italian center.

Algorithm classifications consistent with treatment types.

More than 80% of patients satisfies or very satisfied.

Wide range of patient profiles in terms of age, gender, cancer types and treatments.

Adopted by all types of HCPs and care centers, private and public, large and small.

High patient satisfaction at 94.1%.

High satisfaction of nurses at 73.0%.

Distribution of clinical classifications varies according to the treatment type, in line with the expected relative toxicity of treatment types.

Strong growth in usage since 2019, recently accelerating with reimbursement start.

Older patients (70+) were as compliant as younger ones (mean 66%, no group difference p = 0.29).

Older patients divided in 2 groups based on the 1st month of monitoring: 'Tolerant' (79%) and 'Non-tolerant' (21%).

Progression-free survival was significantly better in 'Tolerant' patients (64.6% vs 23.4%, p = 0.034).

High remote monitoring compliance of 75.8%.

High satisfaction at 95% (strongly satisfied + satisfied).

85% of patients satisfied with their relationship with their health care team via the platform.

Expected: 300 patients by year for 5 years / First patient in: April 2025.

Discover the study design in the study's page.

Under development.

Discover the study design in the study's page.

Under development

Interim analysis: 337 eligible • analysis ongoing.

Discover the study design in the study's page.

‍

Recruitment started in October 2025. Study ongoing.

Discover the study design in the study's page.

High remote monitoring compliance of 72% during the first month, 59% at 8 months.

Patients divided in 2 groups based on the 1st month of monitoring: 'Healthy' (87%) and 'Poor Health' (13%).

29% increase of progression-free survival at 6 months in the 'Healthy' group (p = 0.17).

14% increase of overall survival at 6 months in the 'Healthy' group (p = 0.15).